APLI — Appili Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$1.99m
- CA$14.23m
- CA$0.10m
Brief: Appili Therapeutics To Commence Trading On Main Board Of The TSX Exchange
Brief: Appili Submits Protocol For A Phase 3 Study Evaluating Favipiravir
Brief: Appili Reports Net Loss And Comprehensive Loss Of $2.6 Mln
Brief: FDA Clears Appili Therapeutics To Expand Its Phase 2 Clinical Trial Of Favipiravir For The Potential Prevention Of Covid-19 At U.S. Long-Term Care Facilities
Brief: Appili Prepares Canadian Long-Term Care Facilities To Enroll Participants In A Clinical Trial Evaluating Favipiravir
Brief: Health Canada Clears Appili Therapeutics' Phase 2 Clinical Trial Evaluating Favipiravir As A Prophylactic Agent Against Covid-19 Outbreaks
Brief: Appili Therapeutics Submits CTA With Health Canada
Brief: Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, As Its Chief Medical Officer
Brief: Appili Announces Upsizing Of Previously Announced Equity Offering
Brief: Appili Therapeutics Announces Pricing Of Overnight Marketed Equity Offering
Brief: Appili Therapeutics Announces Overnight Marketed Equity Offering
Brief: Appili Therapeutics Appoints Juergen Froehlich To Its Board Of Directors
Brief: Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals For Anticipated Launch Of ATI-1501 Antibiotic Candidate In The U.S.
Brief: Appili Therapeutics Names Dr. Armand Balboni As Chief Executive Officer
Brief: Appili Therapeutics Acquires Clinical Stage Antifungal Program From Fujifilm Toyama Chemical
Brief: Appili Therapeutics Reports Q1 Loss Per Share $0.06
Brief: Appili Therapeutics Signs $3M Grant Contract With The United States Department Of Defense To Develop Antibiotics That Target Superbugs
Brief: Appili Therapeutics Common Shares to Begin Trading on June 25, 2019 on the TSXV Under the Stock Symbol “APLI”